Stockscreener 앱 받기
7.02
3.70%
-0.27
시간 외 거래:
7.02
전일 마감가:
$7.29
열려 있는:
$7.42
하루 거래량:
300.89K
Relative Volume:
1.39
시가총액:
$228.45M
수익:
$128.45M
순이익/손실:
$6.54M
주가수익비율:
140.40
EPS:
0.05
순현금흐름:
$-8.79M
1주 성능:
+8.75%
1개월 성능:
+32.70%
6개월 성능:
+14.43%
1년 성능:
+9.86%
1일 변동 폭
$6.98
$7.43
1주일 범위
$6.102
$7.48
52주 변동 폭
$3.6793
$7.99
Lifecore Biomedical Inc Stock (LFCR) Company Profile
명칭
Lifecore Biomedical Inc
전화
(952) 368-4300
주소
3515 LYMAN BOULEVARD, CHASKA
LFCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
7.02 | 228.45M | 128.45M | 6.54M | -8.79M | 0.05 |
|
ZTS
Zoetis Inc
|
158.06 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.38 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.63 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.39 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.70 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-05 | 개시 | Craig Hallum | Buy |
| 2024-08-28 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2023-03-20 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc 주식(LFCR)의 최신 뉴스
Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) hedge funds shareholders had a great week as one-year returns increased after a 11% gain last week - Yahoo Finance
A Piece Of The Puzzle Missing From Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Share Price - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Raises Stock Holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
When the Price of (LFCR) Talks, People Listen - news.stocktradersdaily.com
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference - The Manila Times
Quality Management Expert from Lifecore to Chair Strategic Discussion at Major CDMO Conference - Stock Titan
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Lifecore Appoints Top Legal Executive: Stock Price Targets Set at 5x Current Value - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Lifecore Biomedical Taps Thomas Salus as Chief Legal & Administration Officer - Contract Pharma
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer - GlobeNewswire
Lifecore Strengthens Leadership: Former Viatris Legal Chief Joins to Drive Strategic Growth - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Prudential Financial Inc. Makes New $95,000 Investment in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical secures stockholder nod for share issuance - Investing.com Australia
Lifecore Biomedical secures stockholder nod for share issuance By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Reach Out - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out - markets.businessinsider.com
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lifecore Biomedical, Inc. Under Investigation: Schall Law Firm Encourages Investors with Losses to Reach Out - ACCESS Newswire
Hedge funds owners may consider drastic measures as Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) recent US$65m drop adds to long-term losses - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - markets.businessinsider.com
(LFCR) Investment Analysis - news.stocktradersdaily.com
Lifecore Biomedical’s Earnings Call: Strategic Optimism Amid Challenges - MSN
Lifecore Biomedical Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q3 2025 Earnings Call Transcript - Insider Monkey
Sector Update: Health Care Stocks Fall Late Afternoon - MarketScreener
Top Midday Decliners - MarketScreener
Lifecore Biomedical earnings missed by $0.33, revenue topped estimates - Investing.com Canada
Lifecore Biomedical Inc (LFCR) Q3 2025 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Lifecore Biomedical Reports Q3 Fiscal 2025 Results - TipRanks
Lifecore Biomedical (LFCR) Maintains Outlook Amid Strategic Grow - GuruFocus
Lifecore Biomedical targets 12% revenue CAGR and expanded CDMO pipeline by 2027 - MSN
Lifecore Biomedical: Fiscal Q3 Earnings Snapshot - MySA
Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results - MarketScreener
Lifecore Biomedical Inc reports results for the quarter ended February 28Earnings Summary - TradingView
Lifecore Biomedical Q3 Swings to Loss, Revenue Lower - MarketScreener
Lifecore Biomedical Inc (LFCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
0.06%
자본화:
|
볼륨(24시간):